Public Policy Resources

Share

Woman seeing her physician

Access to Health Care

ACS CAN advocates for policies that provide access to treatments and services people with cancer need for their care - including those who may be newly diagnosed, in active treatment and cancer survivors.

Access to Health Care Resources:

Congress Must Make Permanent the ACA Enhanced Tax Credits

May 10, 2024

Having affordable and comprehensive health insurance coverage is a key determinant for surviving cancer.

Congress Must Make Permanent the ACA Enhanced Tax Credits

May 10, 2024

Having affordable and comprehensive health insurance coverage is a key determinant for surviving cancer.

Congress Must Make Permanent the ACA Enhanced Tax Credits

May 10, 2024

Having affordable and comprehensive health insurance coverage is a key determinant for surviving cancer.

Survivor Views: Majority of Cancer Patients & Survivors Have or Expect to Have Medical Debt

May 9, 2024

Our latest survey finds that about half of cancer patients and survivors (49%) have incurred medical debt to pay for their cancer care and another 13% expect to incur medical debt as they begin or continue their treatment. Nearly all of those (98%) had health care coverage at the time they accumulated medical debt. This survey also explores the broad health and financial implications of medical debt, how medical debt deepens inequites, and the alarming rate of cancer related medical debt among younger respondents with early diagnoses.

ACS and ACS CAN letter regarding CMS data

March 22, 2024

Addressing Cancer Disparities in LGBTQ+ Communities

March 20, 2024

A critical factor for eliminating disparities and ensuring health equity is the guarantee that all people have access to quality, affordable health care.

Factors Influencing Cancer Disparities

January 11, 2024

The American Cancer Society Cancer Action Network (ACS CAN) believes everyone should have a fair and just opportunity to prevent, detect, treat, and survive cancer. No one should be disadvantaged in their fight against cancer because of income, race, gender identity, sexual orientation, disability status, or where they live. From preventive screening and early detection, through diagnosis and treatment, and into survivorship, there are several factors that influence cancer disparities among different populations across the cancer continuum.

Medicare’s Six Protected Classes Explained

November 14, 2023

In 2003, Congress passed the Medicare Modernization Act (MMA), which created an outpatient prescription drug benefit in the Medicare program. Known as Part D, the prescription benefit is operated exclusively through private insurance plans that contract with Medicare. To ensure that beneficiaries have coverage for the drugs they need Part D plans are required to cover at least two drugs in each therapeutic class. A therapeutic class is a group of medications that are used to treat the same condition. 

Survivor Views: One in Ten Impacted by Recent Drug Shortages

October 19, 2023

The nation’s drug shortage crisis continues to affect cancer patients and survivors with 1 in every 10 (10%) reporting impacts to care, a majority of whom have had difficulties finding substitute medications (68%) and cited treatment delays (45%).

Prescription Drug Affordability Resources:

Patient Assistance Programs

November 1, 2023

Patient Assistance Programs

Comments to CMS re: Medicare Drug Price Negotiation Program

September 12, 2023

Survivor Views: Copay Assistance and Patient Navigation

July 18, 2022

Prescription drug costs are a significant burden on cancer patients and survivors, sometimes even leading patients to miss or delay taking prescribed medications. The latest Survivor Views survey explores the role copay assistance programs can play in reducing this burden, and also addresses patient navigation and digital therapeutics.

Survivor Views: Affordability, Prescription Drugs, & Pain

December 15, 2021

A majority of cancer patients and survivors struggle to afford cancer care and over 80% have had to make financial sacrifices to cover their health care expenses. This survey also reveals ways that affordability concerns can negatively impact care and treatment, and explores issues related to prescription drug coverage and pain management options.

Some Patients Lack Access to Lower-cost Drug Alternatives

November 3, 2020

Many cancer patients take multiple drugs as part of their treatment – often for many months or years. While drugs are not the only costly part of cancer treatment, finding ways to reduce these costs for patients and payers will significantly reduce the overall cost burden of cancer.

Survivor Views: Surprise Billing and Prescription Cost and Coverage Survey Findings Summary

December 4, 2019

This Survivor Views survey examined access to and affordability of cancer care. Survivors report insurance-related barriers to obtaining prescriptions, and lower-income respondents in particular have difficulty affording them.  24% of respondents have received a surprise medical bill, 60% of which were more than $500.

Understanding Biologic and Biosimilar Drugs

July 27, 2018

Biological drugs, commonly referred to as biologics, are a class of drugs that are produced using a living system, such as a microorganism, plant cell, or animal cell. Like all drugs, biologics are regulated by the United States Food and Drug Administration (FDA).

Formulary Transparency Helps Cancer Patients

October 6, 2017

For an individual with specific health care needs – like cancer patients and survivors – the drugs covered by a health plan and corresponding cost sharing for each drug is important information when choosing health insurance. However, to make an informed choice, formulary information must be disclosed to the individual.

Private Health Insurance Resources:

ACS CAN Examination of Cancer Drug Coverage and Transparency in the Health Insurance Marketplaces

November 18, 2015

In 2015, the American Cancer Society Cancer Action Network (ACS CAN) analyzed coverage of cancer drugs in the health insurance marketplaces created by the Affordable Care Act (ACA) and found that transparency of coverage and cost-sharing requirements were insufficient to allow cancer patients to choose the best plan for their needs.

Cancer Drug Coverage in Health Insurance Marketplace Plans (2014)

March 1, 2014

This analysis examines two issues of particular interest to the American Cancer Society Cancer Action Network (ACS CAN) and its members: the extent of coverage and cost-sharing for cancer drugs, and whether information on the coverage of cancer drugs can be readily obtained, compared, and understood by patients.

Spending to Survive: Cancer Patients Confront Holes in the Health Insurance System

January 30, 2009

This report highlights the severe challenges cancer patient may face in paying for life-saving care even when they have private health insurance.

  •  

Medicaid Resources:

ACS CAN Comments to CMS re: OK 1115 Waiver

April 20, 2021

ACS CAN comments supporting Medicaid expansion in Oklahoma, but opposing their proposal to rescind retroactive eligibility

Medicaid Section 1115 Research and Demonstration Waivers

January 10, 2020

An increasing number of states are seeking greater flexibility in administering their Medicaid programs. The Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) give states the opportunity to test innovative or alternative approaches to providing health care coverage to their Medicaid populations through Section 1115 Research and Demonstration Waivers (otherwise known as "1115 waivers"). States must demonstrate that their waivers promote the objectives of the Medicaid and Children’s Health Insurance Programs (CHIP) and CMS must use general criteria to determine whether the objectives of the Medicaid/CHIP programs are met.

  •